Sign in
Taking people in NetherlandsPhase 2

Folate PET scan to track anti-TNF response in rheumatoid arthritis

Tests a folate PET scan to track anti-TNF treatment response in adults with rheumatoid arthritis.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Amsterdam and Groningen, NetherlandsSee the 2 sites
Registry title
[18F]PEG-folate PET-CT imaging for monitoring of therapy response in Rheumatoid Arthritis patients
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
27 Nov 2024
Expected to end
1 Jun 2027
Type of study
Interventional
Record updated
5 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active rheumatoid arthritis who have a clinical reason to start or restart anti-TNF treatment. A special scan (Folate PET/CT) is used to follow how treatment works.

Age
18 years or older
Sex
All sexes can join
Disease stage
Rheumatoid arthritis with active disease and arthritis in at least one joint that a biopsy can reach.
Earlier treatment
Anti-TNF treatment is needed (infliximab, etanercept, adalimumab or certolizumab). One earlier anti-TNF drug is allowed, but not if it did not work in the first 12 weeks. DMARDs, oral steroids up to 10 mg daily and NSAIDs are allowed at a stable dose for at least 4 weeks.

Main reasons for not taking part

  • Steroid injections into the muscle or vein in the 4 weeks before screening
  • Methotrexate and folic acid taken less than 7 days before the tracer injection
  • Any investigational drug in the past 3 months
  • Known pregnancy or breastfeeding
  • Research-related radiation exposure of 5 mSv or more in the past year

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Patients must be at least 18 years of age - Diagnosis of rheumatoid arthritis according to the 1987 revised criteria of the American Rheumatism Association (ARA)13 and/or the 2010 ACR/EULAR Rheumatoid Arthritis classification criteria. - Patients with clinically active disease as assessed by a physician; with arthritis in at least one joint accessible to synovial biopsy and have a clinical indication to (re)start with anti-TNF (either Infliximab, Etanercept, Adalimumab or Certolizumab). - Prior treatment with one anti-TNF agent (Adalimumab, Certolizumab, Etanercept, Golimumab or Infliximab) is permitted, but may not be a primary failure to any anti-TNF agent (defined as no response within the first 12 weeks of treatment). Patients restarting previously successful aTNF treatment after a >3 month period are also allowed, provided the initial reason for stopping treatment was not ineffectiveness (such as surgery or an infection). - Treatment with disease modifying anti-rheumatic drugs (DMARDS) and oral corticosteroid up to 10 mg daily is allowed, provided that there is a stable dose for at least 4 weeks prior to inclusion and during the study up to 12 weeks of follow up. - Non-steroidal anti-inflammatory drugs (NSAID) is permitted, provided that there is a stable dose for at least 4 weeks prior to inclusion and during the study up to 12 weeks of follow up. - Patients must be able to adhere to the study appointments and other protocol requirements - Patients must be capable of giving informed consent and the consent must have been obtained prior to the study related procedures

Who cannot take part

  • A potential subject who meets any of the following criteria will be excluded from participation in this study: - Use of intramuscular or intravenous corticosteroids within 4 weeks prior to screening. - Patients who received methotrexate and folic acid less than 7 days before tracer injection - Treatment with any investigational drug within the previous 3 months - Known pregnancy or breast feeding - Research related radiation exposure (cumulative ≥5 mSv) in the year before inclusion

Where in Netherlands

  • Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
  • Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people

About the trial

What the trial wants to find out

The primary objective is to investigate the association between quantitative changes in whole body [18F]PEG Folate PET/CT (Folate PET) after 4 weeks and clinical response to anti-TNF therapy at 26 weeks of treatment in patients with clinically active established RA. The secondary objective is to relate quantitative Folate PET outcome after 4 weeks to histological changes in synovial tissue after 4 weeks of anti-TNF treatment (with a particular focus on macrophage infiltration and FRβ expression).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
[18F]PEG-folate PET-CT imaging for monitoring of therapy response in Rheumatoid Arthritis patients
Plain-language title
Folate PET scan to track anti-TNF response in rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 October 2026